Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Evidence desk

The evidence behind the decisions

Guidelines, primary studies and drug labels, with their different roles kept visible.

Targeted evidence update: 11 November 2026 · Baseline literature and label search: 26 September 2026

01 · ACR guideline for management of gout

2020 · Guideline

ULT indications, initial therapy, targets and prophylaxis.

Open original source ↗
02 · NICE NG219: Gout—recommendations

2022 · Guideline

Diagnosis, repeat urate after a flare, titration and severe-disease targets.

Open original source ↗
03 · EULAR recommendations on imaging in crystal-induced arthropathies

2023 recommendations; published 2024 · Guideline

Modality selection and distinction between deposition and symptoms.

Open original source ↗
04 · ACR/EULAR CPPD classification criteria

2023 · Classification study

Research classification; not a standalone diagnostic test.

Open original source ↗
05 · EULAR CPPD recommendations: terminology and diagnosis

2011 · Guideline

Phenotypes and associated metabolic conditions.

Open original source ↗
06 · SANJO: septic arthritis in native joints

2023 · Guideline

Crystals do not exclude infection; aspiration and microbiology priorities.

Open original source ↗
07 · ACR patient resource: CPPD

Updated 2025 · Professional-society patient resource

Patient explanation, associations and limits of current therapy.

Open original source ↗
08 · Imaging features of CPPD: multidisciplinary consensus definitions

2023 · Consensus research

Anatomic imaging features and modality limitations.

Open original source ↗
09 · ACR patient resource: gout

Updated 2025 · Professional-society patient resource

Patient overview and medication roles.

Open original source ↗
10 · COLCRYS prescribing information

Label accessed 2026-09-25 · U.S. drug label

Adult flare regimen, organ impairment and drug interactions; verify product-specific current label before prescribing.

Open original source ↗
11 · Updated EULAR recommendations for gout management

2016; published 2017 · Guideline

Severe-gout target and long-term urate-lowering approach.

Open original source ↗
12 · Allopurinol dose escalation to target serum urate

2017 · Randomized trial

Evidence for monitored escalation rather than a fixed maintenance ceiling.

Open original source ↗
13 · Allopurinol prescribing information

Revised 2026 · U.S. drug label

Hypersensitivity precautions and thiopurine interactions.

Open original source ↗
14 · CARES: cardiovascular safety of febuxostat or allopurinol

2018 · Randomized trial

Mortality signal in patients with established cardiovascular disease.

Open original source ↗
15 · FAST: long-term cardiovascular safety of febuxostat

2020 · Randomized trial

Different population and design from CARES; noninferiority result.

Open original source ↗
16 · Febuxostat prescribing information

Label accessed 2026-09-25 · U.S. drug label

Boxed warning, indication restrictions and thiopurine contraindication.

Open original source ↗
17 · Nurse-led education and treat-to-target gout care

2018 · Randomized trial

Education, engagement and a structured treatment pathway.

Open original source ↗
18 · KRYSTEXXA prescribing information

Label accessed 2026-09-25 · U.S. drug label

Methotrexate co-therapy, G6PD, infusion monitoring and urate stopping guidance.

Open original source ↗
19 · COLCHICORT

2023 · Open-label randomized trial

Short-term colchicine versus prednisone in older hospitalized adults.

Open original source ↗
20 · Prednisolone 10 versus 30 mg for acute CPP crystal arthritis

2024 · Open-label randomized trial

Small comparative dose trial; not a universal dosing protocol.

Open original source ↗
21 · EULAR CPPD recommendations: management

2011 · Guideline

Symptom control and prevention; limited underlying trial base.

Open original source ↗
22 · Methotrexate in chronic-recurrent CPPD

2014 · Randomized crossover trial

No significant benefit demonstrated; limits claims for MTX.

Open original source ↗
23 · Anakinra versus prednisone in acute CPPD

2021 · Randomized pilot study

Small pilot evidence; off-label specialist use is distinct from routine care.

Open original source ↗
24 · Histopathology and ultrastructure in Milwaukee shoulder

1984 · Primary pathology study

BCP aggregates and limits of conventional microscopy.

Open original source ↗
25 · Lavage with steroid versus sham in calcific shoulder tendinopathy

2023 · Sham-controlled randomized trial

No benefit over sham in the studied population; procedure counseling.

Open original source ↗
26 · Milwaukee shoulder: fifteen additional cases

1990 · Case series

Destructive arthropathy phenotype and fluid findings.

Open original source ↗
27 · Calcium oxalate arthropathy in dialysis

1988 · Case report

Rare-disease illustration; not comparative treatment evidence.

Open original source ↗
28 · DASH-patterned groceries in gout

2021 · Randomized pilot study

Dietary intervention remains adjunctive; pilot limitations.

Open original source ↗
29 · CPIC: HLA-B genotype and allopurinol dosing — 2015 update

2015 · Pharmacogenetic guideline

Interpreting HLA-B*58:01 results and selecting an alternative for carriers.

Open original source ↗
30 · MSU crystals activate the NALP3/NLRP3 inflammasome

2006 · Primary mechanistic study

Crystal sensing, caspase-1 and IL-1β activation.

Open original source ↗
31 · Synovial cytokines across the stages of acute gout

2012 · Primary human study

IL-1β, IL-6, IL-8, TNF and the resolution phase.

Open original source ↗
32 · ILARIS (canakinumab) prescribing information

Current label accessed 2026-09-26 · U.S. drug label

Restricted adult gout-flare indication, 150 mg dose, ≥12-week retreatment interval and infection precautions.

Open original source ↗
33 · Anakinra for gout flares: randomized phase II trial

2021 · Randomized trial

Pain improvement with anakinra versus triamcinolone in patients unsuitable for conventional therapy; no superiority on the primary endpoint.

Open original source ↗
34 · KINERET (anakinra) prescribing information

Current label accessed 2026-09-26 · U.S. drug label

IL-1 receptor blockade, renal clearance, neutrophil and infection monitoring; gout is off-label in the U.S.

Open original source ↗
35 · KDIGO guideline for evaluation and management of CKD

2024 · Guideline

Section 3.14: treat symptomatic hyperuricemia; do not use urate lowering solely to delay CKD in asymptomatic hyperuricemia.

Open original source ↗
36 · CKD-FIX: allopurinol and CKD progression

2020 · Randomized trial

No slowing of eGFR decline in the studied progressive-CKD population without gout.

Open original source ↗
37 · PERL: allopurinol and kidney function in type 1 diabetes

2020 · Randomized trial

No clinically meaningful kidney benefit from urate lowering in the studied type 1 diabetes population.

Open original source ↗
38 · ALL-HEART: allopurinol in ischemic heart disease

2022 · Randomized trial

No cardiovascular event reduction in patients with ischemic heart disease without gout.

Open original source ↗
39 · LoDoCo2: colchicine in chronic coronary disease

2020 · Randomized trial

Reduced composite cardiovascular events with 0.5 mg daily in selected chronic coronary disease.

Open original source ↗
40 · COLCOT: low-dose colchicine after myocardial infarction

2019 · Randomized trial

Reduced composite cardiovascular events after recent myocardial infarction in the studied population.

Open original source ↗
41 · CLEAR SYNERGY: colchicine in acute myocardial infarction

Online 2024; issue 2025 · Randomized trial

Neutral cardiovascular primary endpoint; benefit cannot be assumed across all post-MI settings.

Open original source ↗
42 · LODOCO (colchicine 0.5 mg) prescribing information

Current label accessed 2026-09-26 · U.S. drug label

Specific cardiovascular indication, contraindications and interacting medicines.

Open original source ↗
43 · CANTOS: IL-1β inhibition in atherosclerotic disease

2017 · Randomized trial

Cardiovascular proof of concept in post-MI patients with residual inflammation; fatal infection signal.

Open original source ↗
44 · Treat-to-target ULT and cardiovascular outcomes in gout

2026 · Observational target trial emulation

109,504 patients; target achievement associated with fewer cardiovascular events; not randomized proof of protection.

Open original source ↗
45 · Target serum urate and CKD progression in gout

Online 2024; issue 2025 · Observational target trial emulation

In gout with stage 3 CKD, target achievement associated with lower severe/end-stage kidney disease risk; residual confounding remains.

Open original source ↗
46 · DAPA-CKD: dapagliflozin in chronic kidney disease

2020 · Randomized trial

Kidney and heart-failure benefits in eligible CKD patients; not a trial of gout treatment.

Open original source ↗
47 · SGLT2 inhibitors, recurrent gout flares and mortality

2023 · Observational cohort

Lower recurrent flare rates in gout with type 2 diabetes; not evidence to replace urate-lowering therapy.

Open original source ↗
48 · Purine-rich foods, dairy and incident gout

2004 · Prospective cohort

Different associations for animal purines, purine-rich vegetables and dairy; observational dietary evidence.

Open original source ↗
49 · DASH dietary pattern and gout risk

2017 · Prospective cohort

Healthy dietary pattern associated with lower gout risk; prevention cohort is not a gout treatment trial.

Open original source ↗
50 · Musculoskeletal Health Australia: gout and CPPD self-care

Accessed 2026-09-26 · Patient organization guidance

No evidence that calcium-rich food triggers CPP attacks; maintain appropriate dietary calcium.

Open original source ↗
51 · AUA: medical management of kidney stones

2014 guideline; validity confirmed 2019 · Guideline

Stone-specific treatment: urine alkalinization for uric acid stones and selected allopurinol use.

Open original source ↗
52 · Dapansutrile for gout flares

2020 · Open-label phase 2a study

Early proof of concept for direct NLRP3 inhibition; does not establish routine clinical use.

Open original source ↗
53 · Probenecid prescribing information

Current label accessed 2026-09-26 · U.S. drug label

Uricosuric mechanism, renal limitations, stone risk and interactions.

Open original source ↗
54 · MIRROR RCT: pegloticase plus methotrexate

2023 · Randomized trial

Improved sustained urate response with methotrexate co-therapy.

Open original source ↗
55 · Gout flares and subsequent cardiovascular events

2022 · Observational study

Transient association after flares; does not by itself establish causation or a preventive drug effect.

Open original source ↗
56 · NIAMS: gout diagnosis, treatment and steps to take

Accessed 2026-09-26 · NIH patient guidance

Medication roles, dietary changes and management of other health conditions.

Open original source ↗
57 · NIAMS: gout symptoms, causes and risk factors

Accessed 2026-09-26 · NIH patient guidance

Tophi, tissue damage and associated kidney and cardiovascular disease.

Open original source ↗
58 · REDUCE-2: pozdeutinurad (AR882)

2026 · ACR conference abstract · Phase III randomized trial

Urate response at six months in 811 randomized participants. Conference findings; the urate endpoint does not establish prevention of organ damage.

Open original source ↗
59 · Early versus deferred urate-lowering therapy during a flare

2026 · ACR conference abstract · Pragmatic randomized trial

Korean trial: 298 randomized, 288 in the modified intention-to-treat analysis. Similar mean pain changes did not meet the prespecified noninferiority criterion.

Open original source ↗
60 · SSGJ-613 for acute gout flares

2026 · ACR conference abstract · Phase III randomized trial

Chinese active-comparator trial of an IL-1β antibody. Conference evidence should not be treated as a U.S. prescribing authorization.

Open original source ↗
61 · BAPTIST: interim synovial and clinical findings in CPPD

2026 · ACR conference abstract · Phase II interim analysis

Early baricitinib study with 11 participants at baseline and nine at week 12; no consistent clinical or patient-reported improvement pattern. Too small and preliminary to establish benefit or safety.

Open original source ↗
62 · Smartphone-assisted treat-to-target gout care

4 November 2026 · Full journal report · Randomized trial

Single-center, open-label trial in 280 men: the care package included education, reminders, remote urate monitoring and weekly physician review. Its result cannot be attributed to an app alone.

Open original source ↗
63 · ASGARD: anakinra versus methylprednisolone in gout with CKD

30 September 2026 · Full journal report · Feasibility randomized trial

Recruitment fell short: 21 randomized and 17 treated. This report informs trial feasibility, not a reliable comparative efficacy conclusion.

Open original source ↗
64 · DISSOLVE I and II: nanoencapsulated sirolimus plus pegadricase

25 June 2026 · Full journal report · Two phase III trials

Pooled results for 265 treated participants. NASP is a different combination from pegloticase with methotrexate; cross-trial comparisons cannot establish superiority.

Open original source ↗
65 · NASP: sponsor report of FDA complete response letter

26 June 2026 · Sponsor regulatory announcement

Sobi reported requests concerning manufacturing controls and facilities. This dated announcement is regulatory context, separate from the efficacy publication.

Open original source ↗
66 · NICE: shockwave therapy for calcific shoulder tendinopathy

2022 guidance; transferred to HTG645 in 2026 · Procedure guidance

Efficacy evidence is inadequate; NICE recommends use only in research. Transfer to the HealthTech numbering system did not constitute a new efficacy finding.

Open original source ↗
67 · AAOS: calcific tendinitis of the shoulder

Professional-society patient resource · Accessed 11 November 2026

Describes nonsurgical care and consideration of surgery for symptoms persisting despite such treatment. It is educational guidance, not a randomized comparison of procedures.

Open original source ↗
68 · Hydroxychloroquine for chronic CPPD

1997 · Small prospective trial

A small older study underlies part of the hydroxychloroquine discussion in EULAR 2011. The limited evidence does not establish deposit clearance or a robust long-term disease-modifying effect.

Open original source ↗
69 · EULAR management recommendations catalogue

Guideline catalogue · Checked 11 November 2026

The relevant management frameworks identified in this review remain EULAR gout 2016 and CPPD 2011. Newer classification and imaging recommendations address different questions.

Open original source ↗

Educational material, not individual medical advice. This personal publication is not a clinic portal. Urgent problems require direct medical care. Any paid services are private and separate from clinic accounts; they are not billed to insurance.

© Olga Goodman, MD · RheumaView. Copying or redistribution requires author and source credit.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Crystal arthritis